Abstracts Archive - Page 1364 of 2607 - ACR Meeting Abstracts

Abstract Number: 2667 • 2018 ACR/ARHP Annual Meeting
Sledai and Mex-Sledai Glucocorticoid Indices As Predictors of Damage and Mortality in Multinational Multiethnic Latin American Cohort
Manuel Ugarte-Gil^1,2, Ines Segami^3,4, Guillermina Harvey⁵, Guillermo J. Pons-Estel⁶, Rosana Quintana⁷, Cristina Reategui-Sokolova⁸, Jorge Cieza⁴, Luis J. Catoggio⁹, Mercedes Garcia¹⁰, Verónica Saurit¹¹, Francisco Caeiro¹², Cristina Drenkard¹³, Guillermo Berbotto¹⁴, Emilia Sato¹⁵, Lilian Costallat¹⁶, Eloisa Bonfa¹⁷, Joao C. Tavares Brenol¹⁸, Nilzio A Da Silva¹⁹, Fernando Cavalcanti²⁰, Antonio Iglesias-Gamarra²¹, Marlene Guibert-Toledano²², Gil A. Reyes²², Loreto Massardo²³, Oscar J Neira²⁴, Mario H Cardiel²⁵, Leonor Barile²⁶, Mary Carmen Amigo²⁷, Luis H. Silveira²⁸, Ignacio Garcia de la Torre²⁹, Eduardo Acevedo-Vasquez², Rosa Chacón-Díaz³⁰, Maria H Esteva Spinetti³¹, Graciela S. Alarcón^32,33 and Bernardo A Pons-Estel⁷, ¹Rheumatology, Universidad Científica del Sur, Lima, Peru, ²Hospital Guillermo Almenara Irigoyen. EsSalud, Lima, Peru, ³Universidad Nacional Mayor de San Marcos, Lima, Peru, ⁴Hospital Edgardo Rebagliati Martins. EsSalud, Lima, Peru, ⁵Escuela de Estadística, Universidad Nacional de Rosario, Rosario, Argentina, ⁶Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario. Argentina, Rosario, Argentina, ⁷Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Rosario, Argentina, ⁸Rheumatology, Hospital Guillermo Almenara Irigoyen. EsSalud, Lima, Peru, ⁹Rheumatology Unit, Internal Medicine Service. Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ¹⁰Rheumatology, HIGA General San Martin La Plata, La Plata, Argentina, ¹¹Hospital Privado Centro Médico de Córdoba, Cordoba, Argentina, ¹²Rheumatology, Hospital Privado Centro Médico de Córdoba, Córdoba, Argentina, ¹³Medicine/Rheumatology, Emory University, Atlanta, GA, ¹⁴Hospital Escuela Eva Perón, Granadero Baigorria, Argentina, Granadero Baigorria, Argentina, ¹⁵Rheumatology Division, Universidade Federal de Sao Paulo, Sao Paulo, Brazil, ¹⁶Universidade Estadual da Campinas, Campinas, Brazil, ¹⁷Rheumatology Division, Hospital das Clinicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, ¹⁸Hospital da Clinicas da Porto Alegre, Porto Alegre, Brazil, ¹⁹Faculdade de Medicina da Universidade Federal de Goiás, Goiania, Brazil, ²⁰Universidade Federal da Pernambuco, Pernambuco, Brazil, ²¹Universidad Nacional de Colombia, Bogota, Colombia, ²²Centro de Investigaciones Médico-Quirúrgicas (CIMEQ), Havana, Cuba, ²³Centro de Biología Celular y Biomedicina (CEBICEM), Universidad San Sebastián, Santiago, Chile, ²⁴Hospital del Salvador, Facultad de Medicina, Universidad de Chile, Santiago, Chile, ²⁵Centro de Investigación Clínica de Morelia, Morelia, Mexico, ²⁶Hospital Ángeles del Pedregal, Mexico, Mexico, ²⁷Rheumatology, Centro Medico ABC, Mexico, Mexico, ²⁸Rheumatology, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City DF, Mexico, ²⁹Hospital General de Occidente, Guadalajara, Mexico, ³⁰Servicio de Reumatología, Hospital Universitario de Caracas, Centro Nacional de Enfermedades Reumáticas, Caracas, Venezuela, ³¹Hospital Central de San Cristóbal, San Cristobal, Venezuela (Bolivarian Republic of), ³²Universidad Peruana Cayetano Heredia, Lima, Peru, ³³Department of Medicine, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Disease activity is one of the major predictors of damage accrual and mortality in systemic lupus erythematosus (SLE). Glucocorticoid use, especially in high dose,…
Abstract Number: 2668 • 2018 ACR/ARHP Annual Meeting
Hydroxychloroquine and the Risk of Thrombotic Events in Systemic Lupus Erythematosus Patients : A Systematic Review and Meta-Analysis
Pratyaksha Sankhyan¹, Boonphiphop Boonpheng² and Christopher Cook², ¹Internal Medicine, East Tennessee State University, Johnson city, TN, ²Internal Medicine, East Tennessee State University, johnson city, TN
Hydroxychloroquine and Risk of Thrombosis in Patients with Systemic Lupus Erythematosus: A Systematic Review and Meta-analysisAuthors : Sankhyan P, Boonpheng B, Cook CT Background/Purpose: Over…
Abstract Number: 2669 • 2018 ACR/ARHP Annual Meeting
Assessing the Need for Pneumocystis Jiroveci Pneumonia (PCP) Prophylaxis in SLE Patients on Immunosuppression
Kimberly A. Lynch¹, Maria Salgado Guerrero², Alejandra Londono Jimenez¹, Inessa Gendlina³, Wenzhu B. Mowrey⁴, Michele H. Mokrzycki⁵ and Anna R. Broder⁶, ¹Internal Medicine, Montefiore Medical Center, Bronx, NY, ²Internal Medicine, Jacobi Medical Center, Bronx, NY, ³Infectious Disease, Albert Einstein College of Medicine, Bronx, NY, ⁴Albert Einstein College of Medicine, Bronx, NY, ⁵Nephrology, Montefiore Medical Center, Bronx, NY, ⁶Rheumatology, Montefiore Medical Center, Bronx, NY
Background/Purpose: The risk-benefit of Pneumocystis jiroveci pneumonia (PCP) prophylaxis in systemic lupus erythematosus (SLE) is not well defined and there are no SLE-specific guidelines. On…
Abstract Number: 2670 • 2018 ACR/ARHP Annual Meeting
Association of Hydroxychloroquine Use and Incident Atrial Fibrillation in Systemic Lupus Erythematosus: A Retrospective Study
Alisha Gupta¹, Aditya Joshi¹, Mary Chester-Wasko² and Tarun S. Sharma³, ¹Internal Medicine, Allegheny General Hospital, Pittsburgh, PA, ²Allegheny Health Network, Pittsburgh, PA, ³Rheumatology, Lupus Center of Excellence, Allegheny Health Network, Pittsburgh, PA
Background/Purpose: Hydroxychloroquine (HCQ) is a derivative of quinidine, a class 1a anti-arrhythmic agent used to prevent ventricular arrhythmias and recurrent atrial fibrillation (AFib). AFib occurs…
Abstract Number: 2671 • 2018 ACR/ARHP Annual Meeting
Development and First-in-Human Characterization of an ICOSL and BAFF Bispecific Inhibitor AMG 570 for SLE Treatment
Laurence E Cheng¹, Hailing Hsu², Martin Kankam³, Nicholas Siebers⁴, Randall Stoltz⁵, Lubna Abuqayyas², Bella Ertik⁶, Barbara Sullivan², Lei Zhou² and Jane R Parnes², ¹Amgen Inc., South San Francisco, CA, ²Amgen Inc., Thousand Oaks, CA, ³Vince and Associates Clinical Research, Inc.,, Overland Park, KS, ⁴Covance, Madison, WI, ⁵Covance, Evansville, IN, ⁶Amgen Inc, Boston, MA
Background/Purpose: Autoimmune diseases, including systemic lupus erythematosus (SLE), are associated with dysregulated T cell and B cell responses. AMG 570 is a bispecific molecule targeting…
Abstract Number: 2672 • 2018 ACR/ARHP Annual Meeting
Serum Vitamin D Levels and Its Effect on Disease Activity and Fatigue in Systemic Lupus Erythematosus Patients
Radka Moravcova¹, Hana Ciferska², Marta Olejarova^3,4, Dana Tegzova⁵, Jakub Zavada⁶ and Milada Lösterova¹, ¹Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University in Prague, Czech Republic, Praque, Czech Republic, ²Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University in Prague, Czech Republic, Prague, Czech Republic, ³Department of Experimental Rheumatology, 1st Faculty of Medicine, Institute of Rheumatology, Charles University in Prague, Prague, Czech Republic, ⁴Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic, ⁵Institute of Rheumatology and Rheumatological Clinic of 1st Medical Faculty, Charles University, Prague, Prague, Czech Republic, ⁶Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune inflammatory disease involving many organs and systems. Evidences show that vitamin D plays an important role…
Abstract Number: 2673 • 2018 ACR/ARHP Annual Meeting
Different Risk Profiles for Development of Steroid-Related and Steroid-Unrelated Damage in Early Diagnosed SLE: Results from the Italian Multicenter Early Lupus Project Inception Cohort
Matteo Piga¹, Gian Domenico Sebastiani², Imma Prevete³, Florenzo Iannone⁴, Laura Coladonato⁵, Marcello Govoni⁶, Alessandra Bortoluzzi⁷, Marta Mosca⁸, Chiara Tani⁸, Andrea Doria⁹, Luca Iaccarino¹⁰, Angela Tincani¹¹, Micaela Fredi¹², Fabrizio Conti¹³, Francesca Spinelli¹⁴, Mauro Galeazzi¹⁵, Francesca Bellisai¹⁶, Anna Zanetti¹⁷, Greta Carrara¹⁸, Carlo Alberto Scirè¹⁹ and Alessandro Mathieu¹, ¹Unit and Chair of Rheumatology, University Hospital of Cagliari, Cagliari, Italy, ²Rheumatology, San Camillo Forlanini Hospital, Roma, Italy, ³Azienda Ospedaliera San Camillo of Rome, Roma, Italy, ⁴Reumatologia Universita e Policlinico di Bari, Bari, Italy, ⁵Reumatologia, Università e Policlinico di Bari, Bari, Italy, ⁶UOC of Rheumatology, University Hospital S. Anna, Cona Ferrara, Italy, ⁷Section of Rheumatology, Department of Medical Sciences, University of Ferrara and Azienda Ospedaliera-University Hospital S. Anna, Cona Ferrara, Italy, ⁸Rheumatology Unit, University of Pisa, Pisa, Italy, ⁹University and Azienda Ospedaliera of Padova, Padova, Italy, ¹⁰Department of Medicine-DIMED, University of Padova, Padova, Italy, ¹¹Department of Clinical and Experimental Sciences, Spedali Civili and University of Brescia, Brescia, Italy, Rheumatology and Clinical Immunology, BRESCIA, Italy, ¹²Department of Clinical and Experimental Sciences, Spedali Civili and University of Brescia, Brescia, Italy, Rheumatology and Clinical Immunology, Brescia, Italy, ¹³Rheumatology Unit, Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, Rome, Italy, ¹⁴Dipartimento di Medicina Interna e Specialita` Mediche, Sapienza Universita` di Roma, Roma, Italy, ¹⁵Rheumatology, University Hospital of Siena, Siena, Italy, ¹⁶UOC di Reumatologia, Azienda Ospedaliera Universitaria Senese, Siena, Italy, ¹⁷Italian Society for Rheumatology, Milano, Italy, ¹⁸Epidemiology Unit, Italian Society for Rheumatology, Milano, Italy, ¹⁹Italian Society for Rheumatology, Milan, Italy
Background/Purpose:Preventing organ damage is a major challenge in Systemic Lupus Erythematosus (SLE).To evaluate factors associated with development of steroid-related and unrelated damage in an inception…
Abstract Number: 2674 • 2018 ACR/ARHP Annual Meeting
Identifying Phenotype Clusters in Systemic Lupus Erythematosus By Damage Cluster
Ga Young Ahn¹, Jiyoung Lee², Eunji Ha³, Kwangwoo Kim³, Hyoungyoung Kim¹, Ji Soong Kim¹, Bora Nam¹, Juyeon Kang¹, Hyuk-Hee Kwon¹, So-Young Bang¹, Hye-Soon Lee¹ and Sang-Cheol Bae¹, ¹Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South), ²Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, Korea, Republic of (South), ³Biology, Kyung Hee University, Seoul, Korea, Republic of (South)
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a multisystem autoimmune disease with complex genetic background. Recently, subphenotype in SLE has influenced dialogue on discussing the genetic…
Abstract Number: 2675 • 2018 ACR/ARHP Annual Meeting
Age-Related Metabolic Changes Underlie Pro-Inflammatory Lineage Specification and Contribute to Therapeutic Responsiveness to Mechanistic Target of Rapamycin Blockade in SLE
Zhi-Wei Lai¹, Ryan Kelly² and Andras Perl¹, ¹Medicine, SUNY Upstate Medical University, Syracuse, NY, ²SUNY, Syracuse, NY
Background/Purpose: Systemic lupus erythematosus (SLE) patients exhibit T-cell dysfunction which can be reversed by blockade of the mechanistic target of rapamycin (mTOR) with therapeutic efficacy…
Abstract Number: 2676 • 2018 ACR/ARHP Annual Meeting
SLE Patients with No Organ Damage Might Benefit More from Belimumab Treatment
Ioannis Parodis^1,2, Sharzad Emamikia^1,2, Alvaro Gomez¹ and Katerina Chatzidionysiou^2,3, ¹Division of Rheumatology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, Stockholm, Sweden, ²Rheumatology, Karolinska University Hospital, Stockholm, Sweden, Stockholm, Sweden, ³Division of Rheumatology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: In systemic lupus erythematosus (SLE), organ damage is associated with unfavourable disease courses and premature mortality. We aimed at investigating the impact of organ…
Abstract Number: 2677 • 2018 ACR/ARHP Annual Meeting
A Systematic Review Examining the Association between Organ Damage and Health-Related Quality of Life in Systemic Lupus Erythematosus
Edward R. Hammond¹, Dora H. Lin², Irene B. Murimi², Henk Nab³, Hong Kan², Oluwadamilola Onasanya², Jonothan Tierce², Xia Wang¹, Barnabas Desta¹ and G. Caleb Alexander², ¹AstraZeneca, Gaithersburg, MD, ²Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, ³AstraZeneca, Cambridge, United Kingdom
Background/Purpose: SLE-related organ damage is associated with increased morbidity. The comorbidity burden of SLE can involve various organ systems and may include pain, fatigue, difficulty…
Abstract Number: 2678 • 2018 ACR/ARHP Annual Meeting
Integrated Safety Profile of Atacicept from All Clinical Studies to Date
Caroline Gordon^1,2, Roberto Bassi³, Peter Chang⁴, Amy H. Kao³, David Jayne⁵, David Wofsy⁶, Victor Ona³ and Patricia Fleuranceau-Morel³, ¹Rheumatology Research Group, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom, ²University of Birmingham, Birmingham, United Kingdom, ³EMD Serono Research & Development Institute, Inc. (a business of Merck KGaA, Darmstadt, Germany), Billerica, MA, ⁴EMD Serono Research & Development Institute, Inc. (a business of Merck KGaA, Darmstadt, Germany), BIllerica, MA, ⁵Department of Medicine, University of Cambridge, Cambridge, United Kingdom, ⁶Rheumatology, University of California, San Francisco, San Francisco, CA
Background/Purpose: We conducted an integrated analysis of pooled safety data from all 17 atacicept clinical studies to date, across multiple indications, to further define atacicept’s…
Abstract Number: 2679 • 2018 ACR/ARHP Annual Meeting
Glucocorticoids Withdrawal in Systemic Lupus Erythematosus: Are Remission and Low Disease Activity Reliable Starting Points for Stopping Therapy? a Real-Life Experience
Viola Signorini, Chiara Tani, Elena Elefante, Chiara Stagnaro, Linda Carli and Marta Mosca, Rheumatology Unit, University of Pisa, Pisa, Italy
Background/Purpose: Glucocorticoids (GC) are a cornerstone of the treatment of Systemic Lupus Erythematosus (SLE); however, a significant organ damage is associated with long-term GC use…
Abstract Number: 2680 • 2018 ACR/ARHP Annual Meeting
Activation Towards Health Self-Management in Patients with Systemic Lupus Erythematosus
Paul R. Fortin¹, Carolyn Neville², Anne-Sophie Julien³, Murray Rochon⁴, Davy Eng⁵, Christine A. Peschken⁶, Evelyne Vinet⁷, Marie Hudson⁸, Doug Smith⁹, Mark Matsos¹⁰, Janet E. Pope¹¹, Ann E. Clarke¹², Stephanie Keeling¹³, J. Antonio Avina-Zubieta¹⁴ and Deborah Da Costa¹⁵, ¹Medicine, CHU de Québec - Université Laval, Québec, QC, Canada, ²Department of Medicine, McGill University Health Center, Montreal, QC, Canada, ³CHU de Québec - Université Laval, Quebec City, QC, Canada, ⁴Jack Digital, Toronto, ON, Canada, ⁵Centre de recherche du CHU de Québec - Université Laval - Axe maladies infectieuses et immunitaires, CHU de Québec - Université Laval, Quebec, QC, Canada, ⁶RR 149G, University of Manitoba, Winnipeg, MB, Canada, ⁷Divisions of Rheumatology and Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada, ⁸Division of Rheumatology, Jewish General Hospital, Lady Davis Institute for Medical Research, Montreal, QC, Canada, ⁹Division of Rheumatology, Department of Medicine, The Ottawa Hospital - University of Ottawa, Ottawa, ON, Canada, ¹⁰Medicine, McMaster University, Hamilton, ON, Canada, ¹¹Department of Medicine, University of Western Ontario, London, ON, Canada, ¹²Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ¹³Department of Medicine, University of Alberta, University of Alberta, Edmonton, AB, Canada, ¹⁴Division of Rheumatology, Department of Medicine, University of British Columbia, Vancouver, BC, Canada, ¹⁵Medicine, McGill University, Montreal, QC, Canada
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with fluctuating levels of disease activity. Control of disease activity is associated with better outcomes…
Abstract Number: 2681 • 2018 ACR/ARHP Annual Meeting
Lupus Primary Care Management Practices
Karin Tse and R. Paola Daly, Lupus Foundation of America, Washington, DC
Background/Purpose: Due to the systemic nature of lupus, individuals may interact with a diverse health care team when experiencing lupus symptoms and before receiving a…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].